Boaz Wong

Ottawa, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

ASO Visual Abstract: The Impact of a Regional Communities of Practice to Improve Quality of Melanoma Care: Setting Guidelines for Preoperative Diagnostic Imaging in Early-Stage Melanoma.

ASO Visual Abstract: The Impact of a Regional Communities of Practice to Improve Quality of Melanoma Care: Setting Guidelines for Preoperative Diagnostic Imaging in Early-Stage Melanoma.

Journal: Annals of surgical oncology

Published: June 14, 2026

Impact of Social Determinants on Melanoma Outcomes in Canada: A Single-Centre Retrospective Study.

Impact of Social Determinants on Melanoma Outcomes in Canada: A Single-Centre Retrospective Study.

Journal: Journal of surgical oncology

Published: March 07, 2025

Author Correction: Octyl itaconate enhances VSVΔ51 oncolytic virotherapy by multitarget inhibition of antiviral and inflammatory pathways.

Author Correction: Octyl itaconate enhances VSVΔ51 oncolytic virotherapy by multitarget inhibition of antiviral and inflammatory pathways.

Journal: Nature communications

Published: December 20, 2024

The Impact of a Regional Community of Practice to Improve Quality of Melanoma Care: Setting Guidelines for Preoperative Diagnostic Imaging in Early-Stage Melanoma.

The Impact of a Regional Community of Practice to Improve Quality of Melanoma Care: Setting Guidelines for Preoperative Diagnostic Imaging in Early-Stage Melanoma.

Journal: Annals of surgical oncology

Published: July 03, 2024

Tepilamide Fumarate as a Novel Potentiator of Virus-Based Therapy.

Tepilamide Fumarate as a Novel Potentiator of Virus-Based Therapy.

Journal: Viruses

Published: May 11, 2024

Appendicitis while on alectinib for non-small cell lung cancer: a tale of two case reports.

Appendicitis while on alectinib for non-small cell lung cancer: a tale of two case reports.

Journal: Frontiers in oncology

Published: March 09, 2024

Evolution in the diagnosis and treatment of carcinoma of unknown primary: a multicenter Canadian analysis.

Evolution in the diagnosis and treatment of carcinoma of unknown primary: a multicenter Canadian analysis.

Journal: The oncologist

Published: March 06, 2024

High throughput screen identifies lysosomal acid phosphatase 2 (ACP2) to regulate IFN-1 responses to potentiate oncolytic VSV∆51 activity.

High throughput screen identifies lysosomal acid phosphatase 2 (ACP2) to regulate IFN-1 responses to potentiate oncolytic VSV∆51 activity.

Journal: Scientific reports

Published: January 16, 2024

Are Positive Biopsy Margins in Melanoma Significant?: A Cohort Study of Micro- Versus Macroscopic Margin Status and Their Impact on Residual Disease and Survival.

Are Positive Biopsy Margins in Melanoma Significant?: A Cohort Study of Micro- Versus Macroscopic Margin Status and Their Impact on Residual Disease and Survival.

Journal: Annals of surgical oncology

Published: January 08, 2024

Unlocking the potential of dimethyl fumarate: enhancing oncolytic HSV-1 efficacy for wider cancer applications.

Unlocking the potential of dimethyl fumarate: enhancing oncolytic HSV-1 efficacy for wider cancer applications.

Journal: Frontiers in immunology

Published: November 03, 2023

Octyl itaconate enhances VSVΔ51 oncolytic virotherapy by multitarget inhibition of antiviral and inflammatory pathways.

Octyl itaconate enhances VSVΔ51 oncolytic virotherapy by multitarget inhibition of antiviral and inflammatory pathways.

Journal: Nature communications

Published: June 07, 2023

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to VSVΔ51 oncolytic virotherapy.

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to VSVΔ51 oncolytic virotherapy.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: June 06, 2023

Showing 1-12 of 23

Last Updated: 09/26/2026